Inhibrx Biosciences INBX
NASDAQ INBX
$98.19 +2.89 (+3.03%)
At close: Oct 21, 2026 · 4:00 PM EDT

Inhibrx Biosciences (INBX) Current Assets (2023 - 2026)

Updated

Inhibrx Biosciences (INBX) reported Current Assets of $142.21 million for Q2 2026, down 26.7% from $193.96 million a year earlier.

Analysis

Inhibrx Biosciences (INBX) Current Assets (2023 - 2026) Analysis & Trends

At the end of FY2025, Inhibrx Biosciences posted Current Assets of $132.83 million, down 17.2% from FY2024.

  • By year, Current Assets came in at $160.4 million in FY2024 (-45.7%) and $295.36 million in FY2023.
  • Five-year quarterly Current Assets spans a low of $132.83 million in Q4 2025 and a high of $295.36 million in Q4 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Current Assets (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 64.67 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 59.77 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 33.67 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 36.68 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 27.35 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 27.97 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 34.96 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn 13.95 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 41.36 Bn
10 Inhibrx Biosciences 1.54 Bn 937.90 Mn - 142.21 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 142.21 Mn
Dec 31, 2025 132.83 Mn
Sep 30, 2025 161.42 Mn
Jun 30, 2025 193.96 Mn
Mar 31, 2025 223.39 Mn
Dec 31, 2024 160.40 Mn
Sep 30, 2024 207.45 Mn
Jun 30, 2024 242.06 Mn
Dec 31, 2023 295.36 Mn
API Access

Inhibrx Biosciences Current Assets API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-assets&ticker=INBX&period=max&api_key=YOUR_API_KEY